140 related articles for article (PubMed ID: 37331654)
1. Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
Zalmai R; Hill LG; Loera LJ; Mosgrove Q; Brown C
J Am Pharm Assoc (2003); 2023; 63(5):1558-1565.e4. PubMed ID: 37331654
[TBL] [Abstract][Full Text] [Related]
2. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR
Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519
[TBL] [Abstract][Full Text] [Related]
3. Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample.
Light AE; Green TC; Freeman PR; Zadeh PS; Burns AL; Hill LG
Subst Use Addctn J; 2024 Apr; 45(2):211-221. PubMed ID: 38258805
[TBL] [Abstract][Full Text] [Related]
4. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
Muzyk A; Smothers ZPW; Collins K; MacEachern M; Wu LT
Subst Abus; 2019; 40(4):476-483. PubMed ID: 31418645
[No Abstract] [Full Text] [Related]
5. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
6. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
8. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
9. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
10. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
11. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
[TBL] [Abstract][Full Text] [Related]
12. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
13. North Carolina community pharmacists' buprenorphine dispensing practices and attitudes.
Carpenter D; Lambert KV; Harless JC; Wilson CG; Davis SA; Zule WA; Ostrach B
J Am Pharm Assoc (2003); 2022; 62(5):1606-1614. PubMed ID: 35643625
[TBL] [Abstract][Full Text] [Related]
14. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
15. A Brief Online Training to Address Pharmacists' Willingness to Dispense Buprenorphine.
Carpenter D; Mashburn P; Viracola C; Marley G; Ostrach B
J Addict Med; 2024 Jan-Feb 01; 18(1):68-70. PubMed ID: 37948129
[TBL] [Abstract][Full Text] [Related]
16. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
[TBL] [Abstract][Full Text] [Related]
17. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
Tutag Lehr V; Nolan C
J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
[TBL] [Abstract][Full Text] [Related]
18. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
[TBL] [Abstract][Full Text] [Related]
19. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]